✦ LIBER ✦

DSM and Diversa agree to develop biocatalysts for drug intermediates

Publisher: Elsevier Science
Year: 2004
Weight: 49 KB
Volume: 2004
Category: Article
ISSN: 1351-4180
DOI: 10.1016/s1351-4180(04)00344-7

No coin nor oath required. For personal study only.

✦ Synopsis

residual biomass. The US' 75 ethanol refineries produced a record 2.8 bn gallons in 2003. At least 12 new ethanol refineries are being built in the US. This is largely attributable to the development of more efficient enzymes, advances in genetically modified maize, and government subsidies. Approximately 5% of global chemical sales are derived in part from industrial biotechnology and this could reach 20% by 2010. Environmental products derived from biotechnology raw materials, for example for the automotive sector, are currently in development.

📜 SIMILAR VOLUMES

DSM and Diversa Corporation sign an agre

DSM and Diversa Corporation sign an agreement to develop biocatalysts for making pharmaceutical intermediates

📂 Article 📅 2004 🏛 Elsevier Science ⚖ 64 KB

## BASF licenses proprietary enzyme Diversa Corp has granted BASF a licence to a proprietary enzyme for the biocatalytic synthesis of a pharmaceutical intermediate. BASF will manufacture the biocatalyst and use it in one of its processes to synthesise a chiral intermediate. Manufacturing Chemist, M